BRPI0013478B8 - medicamento compreendendo inibidor pde e uso de roflumilast - Google Patents

medicamento compreendendo inibidor pde e uso de roflumilast

Info

Publication number
BRPI0013478B8
BRPI0013478B8 BRPI0013478A BR0013478A BRPI0013478B8 BR PI0013478 B8 BRPI0013478 B8 BR PI0013478B8 BR PI0013478 A BRPI0013478 A BR PI0013478A BR 0013478 A BR0013478 A BR 0013478A BR PI0013478 B8 BRPI0013478 B8 BR PI0013478B8
Authority
BR
Brazil
Prior art keywords
roflumilast
medicament
pde inhibitor
treatment
pde
Prior art date
Application number
BRPI0013478A
Other languages
English (en)
Other versions
BR0013478A (pt
BRPI0013478B1 (pt
Inventor
Armin Hatzelmann
Christian Schudt
Christian Weimar
Daniela Bundschuh
Rolf Beume
Ulrich Kilian
Original Assignee
Altana Pharma Ag
Byk Gulden Lomberg Chem Fab
Nycomed Asset Man Gmbh
Nycomed Germany Holding Gmbh
Nycomed Gmbh
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag, Byk Gulden Lomberg Chem Fab, Nycomed Asset Man Gmbh, Nycomed Germany Holding Gmbh, Nycomed Gmbh, Takeda Gmbh filed Critical Altana Pharma Ag
Publication of BR0013478A publication Critical patent/BR0013478A/pt
Publication of BRPI0013478B1 publication Critical patent/BRPI0013478B1/pt
Publication of BRPI0013478B8 publication Critical patent/BRPI0013478B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Seasonings (AREA)
  • Inorganic Insulating Materials (AREA)
  • Dental Preparations (AREA)
  • Medicinal Preparation (AREA)
  • Piezo-Electric Or Mechanical Vibrators, Or Delay Or Filter Circuits (AREA)
  • Lubricants (AREA)

Abstract

patente de invenção: "combinação sinergística". a invenção refere-se à administração combinada de inibidores pde e agonistas adrenoceptores <225>~ 2~ para o tratamento de distúrbios do trato respiratório.
BRPI0013478A 1999-08-21 2000-08-11 medicamento compreendendo inibidor pde e uso de roflumilast BRPI0013478B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99116447 1999-08-21
PCT/EP2000/007852 WO2001013953A2 (en) 1999-08-21 2000-08-11 Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist

Publications (3)

Publication Number Publication Date
BR0013478A BR0013478A (pt) 2002-04-30
BRPI0013478B1 BRPI0013478B1 (pt) 2016-12-06
BRPI0013478B8 true BRPI0013478B8 (pt) 2016-12-27

Family

ID=8238828

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0013478A BRPI0013478B8 (pt) 1999-08-21 2000-08-11 medicamento compreendendo inibidor pde e uso de roflumilast

Country Status (28)

Country Link
US (3) US7056936B2 (pt)
EP (3) EP1671651B1 (pt)
JP (1) JP5038568B2 (pt)
KR (1) KR100701904B1 (pt)
CN (1) CN1202865C (pt)
AT (2) ATE320800T1 (pt)
AU (1) AU777012B2 (pt)
BR (1) BRPI0013478B8 (pt)
CA (2) CA2381802C (pt)
CZ (1) CZ302882B6 (pt)
DE (2) DE60026855T2 (pt)
DK (1) DK1212089T3 (pt)
EA (1) EA006685B1 (pt)
ES (1) ES2260043T3 (pt)
HK (1) HK1047244B (pt)
HR (1) HRP20020158B1 (pt)
HU (1) HU229439B1 (pt)
IL (2) IL147688A0 (pt)
MX (1) MXPA02001830A (pt)
NO (1) NO328340B1 (pt)
NZ (1) NZ517166A (pt)
PL (1) PL200923B1 (pt)
PT (1) PT1212089E (pt)
SI (1) SI1212089T1 (pt)
SK (1) SK287231B6 (pt)
TR (2) TR200909479T2 (pt)
WO (1) WO2001013953A2 (pt)
ZA (1) ZA200201389B (pt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6196201A (en) * 2000-05-25 2001-12-03 Merck Frosst Canada Inc Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
EP1389468A4 (en) * 2001-05-23 2007-01-10 Tanabe Seiyaku Co COMPOSITIONS PROMOTING THE GUISON OF A BONE FRACTURE
CN1537018A (zh) * 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
PL393155A1 (pl) 2001-09-14 2011-03-28 Glaxo Group Limited Pochodne fenetanoloaminy do leczenia chorób układu oddechowego
BR0212582A (pt) * 2001-09-19 2004-10-13 Altana Pharma Ag Combinação
DE60218497T2 (de) * 2001-09-19 2007-11-08 Nycomed Gmbh Kombination eines nsaids und eines pde-4 inhibitors
GB0123951D0 (en) * 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
GB0129395D0 (en) * 2001-12-07 2002-01-30 Pfizer Ltd Pharmaceutical combination
IL162506A0 (en) * 2001-12-14 2005-11-20 Applied Research Systems Ovulation induction
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
ES2298511T3 (es) 2002-04-25 2008-05-16 Glaxo Group Limited Derivados de fenetanolamina.
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
PL377122A1 (pl) 2002-10-28 2006-01-23 Glaxo Group Limited Pochodne fenetanoloaminy do leczenia chorób układu oddechowego
AU2003288169B8 (en) * 2002-11-27 2010-08-26 Astrazeneca Ab Synergistic combination comprising roflumilast and (R,R) -formoterol
JP2006508994A (ja) * 2002-11-27 2006-03-16 アルタナ　ファルマ　アクチエンゲゼルシャフト ロフルミラスト及びホルモテロールを含有する新規の相乗組合せ
PL378247A1 (pl) * 2003-01-14 2006-03-20 Altana Pharma Ag Inhibitory PDE4 w terapii nowotworów komórek limfoidalnych
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
ME00524B (me) 2003-03-10 2011-10-10 Astrazeneca Ab Novi postupak za dobijanje roflumilasta
JPWO2004087151A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 医薬組成物
GEP20084406B (en) * 2003-05-30 2008-06-25 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
WO2006094640A2 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Roflumilast and integrin inhibitor combination and method of treatment
WO2006097456A1 (en) * 2005-03-16 2006-09-21 Nycomed Gmbh Taste masked dosage form containing roflumilast
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
WO2007137417A1 (en) * 2006-05-26 2007-12-06 Neuromed Pharmaceuticals Ltd. Heterocyclic compounds as calcium channel blockers
TW200815054A (en) * 2006-06-19 2008-04-01 Otsuka Pharma Co Ltd Methods of using a thiazole derivative
CN101494980A (zh) * 2006-07-14 2009-07-29 兰贝克赛实验室有限公司 HMG-CoA还原酶抑制剂的多晶型形式及其应用
CA2664378A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as pi3k lipid kinase inhibitors
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
AU2007342223B2 (en) 2007-01-10 2011-02-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
MX2010006421A (es) 2007-12-10 2010-06-25 Novartis Ag Compuestos organicos.
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
EP2300010B1 (en) 2008-06-10 2015-03-04 Novartis AG Pyrazine derivatives as epithelial sodium channel blockers
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
IN2012DN01961A (pt) 2009-08-17 2015-08-21 Intellikine Llc
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
WO2011050325A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
AR081377A1 (es) 2010-05-10 2012-08-29 Gilead Sciences Inc Compuestos de pirazolopiridina bifuncionales
WO2012022796A2 (de) * 2010-08-20 2012-02-23 Boehringer Ingelheim International Gmbh Neue kombinationen
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012098495A1 (en) * 2011-01-19 2012-07-26 Glenmark Pharmaceuticals Sa Pharmaceutical composition that includes revamilast and a beta-2 agonist
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
SG192795A1 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as trk inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013081565A1 (en) * 2011-11-21 2013-06-06 Mahmut Bilgic Pharmaceutical compositions comprising roflumilast and terbutaline
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
RU2660354C2 (ru) 2012-04-03 2018-07-05 Новартис Аг Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
CN103830236A (zh) * 2012-11-21 2014-06-04 岳阳新华达制药有限公司 含有盐酸班布特罗和罗氟司特复方制剂及其制备方法
SG11201505835QA (en) * 2013-01-28 2015-08-28 Incozen Therapeutics Pvt Ltd Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
KR20160141855A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피라진 유도체
PT3134396T (pt) 2014-04-24 2019-12-16 Novartis Ag Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase
PL3134395T3 (pl) 2014-04-24 2018-07-31 Novartis Ag Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CN107207510B (zh) 2014-07-31 2019-11-29 诺华股份有限公司 联合疗法
JOP20190219A1 (ar) * 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
CN113891744A (zh) 2019-06-10 2022-01-04 诺华股份有限公司 用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物
KR20220052934A (ko) 2019-08-28 2022-04-28 노파르티스 아게 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
US11999694B2 (en) 2021-10-29 2024-06-04 Sensorium Therapeutics, Inc. Delivery of therapeutic alkaloid compounds

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545687B2 (de) 1964-09-05 1975-09-04 Hoechst Ag, 6000 Frankfurt 1-(5'-Oxohexyl)-3,7-dimethylxanthin und Verfahren zu seiner Herstellung
CA924721A (en) 1969-06-16 1973-04-17 Chasin Mark Hydrazines and hydrazones of pyrazolopyridine carboxylic acids and esters
GB1361441A (en) 1970-05-13 1974-07-24 Sandoz Ltd Benzonaphthyridine derivatives
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
JPS5229318B2 (pt) 1972-03-30 1977-08-01
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
DE2462367A1 (de) 1974-01-22 1976-11-11 Wuelfing J A Fa 7-(oxoalkyl)-1,3-dialkylxanthine enthaltende arzneimittelzubereitungen
DE2413935A1 (de) 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
FR2390164A1 (fr) * 1977-05-13 1978-12-08 Blanie Paul Association a action anti-asthmatique
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
FR2531085A1 (fr) 1982-07-28 1984-02-03 Adir Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4552891A (en) 1983-09-13 1985-11-12 Eli Lilly And Company Benzothiophene derivatives
GB8406906D0 (en) 1984-03-16 1984-04-18 Akzo Nv Benzo-thiazole and benzothiophene derivatives
DK159431C (da) 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
GB8800397D0 (en) 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
US5142096A (en) 1988-03-31 1992-08-25 Kyowa Hakko Kogyo Co., Ltd. 2,4-dihydroxy-3,5,6-trimethylbenzoic acid compounds
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
WO1990012789A1 (de) 1989-04-17 1990-11-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
RU2104306C1 (ru) 1989-11-13 1998-02-10 Пфайзер Инк. Способ получения оптически активного (2s)- или (2r)-эндо-бицикло[2.2.1]гептан-2-ола, способ получения 5-(3-[(2r)-экзо-бицикло[2.2.1]гепт-2-илокси]-4-метоксифенил)-3,4,5,6-тетрагидропиримидин-2(1н)-она, оптически активный 5-(3-[экзо-бицикло[2.2.1]гепт-2-илокси]4-метоксифенил)-3,4,5,6-тетрагидропиримидин-2(1н)-он, оптически активные промежуточные соединения и способ их получения
GB8929208D0 (en) 1989-12-27 1990-02-28 Almirall Lab New xanthine derivatives
MY105344A (en) 1990-05-16 1994-09-30 Byk Gulden Lomberg Chemische Fabrik New sulphonyl compounds
EP0459505B1 (en) 1990-06-01 1996-10-02 Kyowa Hakko Kogyo Co., Ltd. Imidazonaphthyridine derivatives
BR9106653A (pt) 1990-07-10 1993-06-08 Smithkline Beecham Corp Oxamidas
US5124455A (en) 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
DE59109027D1 (en) 1990-10-16 1998-08-13 Byk Gulden Lomberg Chem Fab Arylpyridazinone
GB9027055D0 (en) 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
JPH04234389A (ja) 1990-12-28 1992-08-24 Sapporo Breweries Ltd ナフチリジン誘導体及びそれを有効成分とする抗潰瘍剤
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
IE73235B1 (en) 1991-03-25 1997-05-21 Akzo Nv 4-aryl-thiazole or imidazole derivatives
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
WO1992019602A1 (de) 1991-04-26 1992-11-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridazine
US5191084A (en) 1991-05-01 1993-03-02 American Home Products Corporation Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents
GB9116039D0 (en) 1991-07-25 1991-09-11 Ucb Sa Substituted cyclopropylamino-1,3,5-triazines
DE69229874T2 (de) 1991-10-09 1999-12-09 Syntex Inc Pyrido pyridazinon und pyridazinthionverbindungen mit pde iv inhibierender wirkung
AU3588693A (en) 1992-01-29 1993-09-01 Smithkline Beecham Corporation N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as TNF and PDE IV inhibitors
AU3481593A (en) 1992-01-29 1993-09-01 Smithkline Beecham Corporation N-(3-phenylpropyl)oxamic acid, oxamate, and oxamide derivatives
JP3042156B2 (ja) 1992-02-20 2000-05-15 田辺製薬株式会社 ナフタレン誘導体、その製法及びその合成中間体
GB9204808D0 (en) 1992-03-04 1992-04-15 Rhone Poulenc Rorer Ltd Novel compositions of matter
US5264437A (en) 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
JP3195352B2 (ja) 1992-04-02 2001-08-06 スミスクライン・ビーチャム・コーポレイション アレルギーおよび炎症疾患の治療用化合物
US5605923A (en) 1992-04-02 1997-02-25 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
JP3199380B2 (ja) 1992-04-02 2001-08-20 スミスクライン・ビーチャム・コーポレイション 化合物
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
AU670949B2 (en) 1992-06-15 1996-08-08 Celltech Limited Trisubstituted phenyl derivatives as selective phosphodiesterase IV inhibitors
PT652868E (pt) 1992-07-28 2005-01-31 Aventis Pharma Ltd Inibidores da fosfodiesterase do amp ciclico
RU95113454A (ru) 1992-12-02 1997-06-10 Пфайзер Инк. (US) Катехольные диэфиры как селективные ингибиторы фдэiv, фармацевтическая композиция, способы лечения
TW263495B (pt) 1992-12-23 1995-11-21 Celltech Ltd
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
GB9309324D0 (en) 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
GB9311282D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd New compositions of matter
JPH0710875A (ja) 1993-06-21 1995-01-13 Green Cross Corp:The 選択的ホスホジエステラーゼｉｖ阻害剤
ES2176252T3 (es) 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
RU2131876C1 (ru) 1993-07-06 1999-06-20 Пфайзер Инк. Бициклические тетрагидропиразолпиридины или их фармацевтически приемлемые соли, фармацевтическая композиция, способ ингибирования фосфодиэстеразы, способ лечения
ATE218549T1 (de) 1993-07-28 2002-06-15 Aventis Pharma Ltd Verbindungen als pde iv und tnf inhibitoren
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
US6300372B1 (en) 1993-07-30 2001-10-09 Smithkline Beecham Corporation 3-Cyano-3-(3,4-disubstituted) phenylcyclohexyl-1-carboxylates
DE4495960D2 (de) 1993-08-19 1996-08-22 Block Medtech Gmbh Phoropter
JPH09502170A (ja) 1993-08-19 1997-03-04 スミスクライン・ビーチャム・コーポレイション フェネチルアミン化合物
US5665754A (en) 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
AU7957894A (en) 1993-10-01 1995-05-01 Smithkline Beecham Corporation Compounds, compositions and treatment of allergies and inflammation therewith
WO1995009623A1 (en) 1993-10-01 1995-04-13 Smithkline Beecham Corporation Anti-allergic, anti-inflammatory compounds, compositions and uses
DE69427485T2 (de) 1993-10-01 2002-04-25 Smithkline Beecham Corp Verbindungen, zubereitungen und behandlung von allergien und entzündungen
WO1995009836A1 (en) 1993-10-01 1995-04-13 Smithkline Beecham Corporation Cyanocyclohexane compounds, compositions, and uses thereof
GB9322828D0 (en) 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
DE69422061T2 (de) 1993-11-26 2000-03-30 Pfizer 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel
US5716967A (en) 1993-11-26 1998-02-10 Pfizer Inc. Isoxazoline compounds as antiinflammatory agents
GB9326699D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
EP0738268B1 (en) 1993-12-22 2004-03-03 Celltech R&amp;D Limited Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
DE69508568T2 (de) 1994-02-17 1999-10-21 American Home Prod Substituierte biphenyl-derivate mit phosphodiesterase inhibierender wirkung
CA2143143A1 (en) 1994-03-08 1995-09-09 Toshihiko Tanaka 3-phenylpyrrolidine derivatives
GB9404706D0 (en) 1994-03-11 1994-04-27 Smithkline Beecham Corp Compounds
WO1995027692A1 (en) 1994-04-08 1995-10-19 Smithkline Beecham Corporation Subtituted biphenyl tnf inhibitors
HRP950288A2 (en) 1994-05-31 1997-08-31 Bayer Ag Oxalylamino-benzofuran- and benzothienyl-derivatives
GB9410877D0 (en) 1994-05-31 1994-07-20 Bayer Ag Heterocyclycarbonyl substituted benzoduranyl-and-thiophenyl-alkanecarboxyclic acid derivatives
EP0685475B1 (en) 1994-05-31 1999-01-13 Bayer Ag Amino-benzofuryl-and thienyl-derivatives
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
CA2193725A1 (en) 1994-06-24 1996-01-04 David Cavalla Aryl derivative compounds and uses to inhibit phosphodiesterase iv acti vity
JP4146894B2 (ja) 1994-07-22 2008-09-10 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロベンゾフラン
MX9701600A (es) 1994-08-29 1997-05-31 Yamanouchi Pharma Co Ltd Derivados de naftiridina novedosos y composicion medicinal de los mismos.
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
KR100237962B1 (ko) 1994-10-12 2000-02-01 그린 마틴 신규한 벤즈옥사졸
FR2725719B1 (fr) 1994-10-14 1996-12-06 Jouveinal Inst Rech Diazepino-indoles inhibiteurs de phosphodiesterases iv
NZ292991A (en) 1994-10-20 1999-02-25 Pfizer Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them
US5703098A (en) 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
DE19510965A1 (de) 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung
TW424087B (en) 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
TW375612B (en) 1995-04-06 1999-12-01 Janssen Pharmaceutica Nv 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same
DE19514568A1 (de) 1995-04-20 1996-10-24 Merck Patent Gmbh Arylalkyl-pyridazinone
EP0829477A4 (en) 1995-05-09 1998-07-08 Nippon Kayaku Kk NOVEL PHYSIOLOGICALLY ACTIVE NA23063 ANALOGS AND THEIR PRODUCTION AND USE METHOD
ES2189871T3 (es) 1995-05-18 2003-07-16 Altana Pharma Ag Ciclohexil-dihidro-benzofuranos.
ATE231501T1 (de) 1995-05-18 2003-02-15 Altana Pharma Ag Phenyldihydrobenzofurane
CA2218548A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited Xanthines and their therapeutic use
WO1996036595A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772196A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772396A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
JPH10147585A (ja) 1996-11-19 1998-06-02 Kyowa Hakko Kogyo Co Ltd 含酸素複素環化合物
AR004471A1 (es) 1995-05-31 1998-12-16 Smithkline Beecham Corp Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen
CA2223624C (en) 1995-06-06 2001-02-20 Pfizer Inc. Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines
US6028086A (en) 1995-06-07 2000-02-22 P Pfizer Inc Catechol diethers derivatives useful as pharmaceutical agents
IL118469A (en) 1995-06-15 2000-08-13 Tanabe Seiyaku Co Naphthalene derivatives their preparation and intermediates thereof
WO1997003967A1 (en) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
KR100332273B1 (ko) 1995-07-26 2002-06-20 디. 제이. 우드, 스피겔 알렌 제이 엔-(아로일)글리신하이드록삼산유도체및이와관련된화합물
ATE239477T1 (de) 1995-08-02 2003-05-15 Darwin Discovery Ltd Chinolone und deren therapeutische verwendung
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
AU7154596A (en) 1995-09-08 1997-03-27 St. Jude Children's Research Hospital Virus protein purification from virosomes
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
US6080396A (en) 1995-09-29 2000-06-27 Japan Science And Technology Corporation Anthracycline compound derivative and pharmaceutical preparation containing the same
GB9523267D0 (en) 1995-11-14 1996-01-17 Sandoz Ltd Organic compounds
NZ322197A (en) 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
HUP9903797A3 (en) 1995-12-05 2001-08-28 Darwin Discovery Ltd Milton Ro Benzofuran carboxamides and sulphonamides, their use for producing medicaments and such medicaments
EP0873311A1 (en) 1995-12-15 1998-10-28 Merck Frosst Canada Inc. Tri-aryl ethane derivatives as pde iv inhibitors
GB9603723D0 (en) 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526558D0 (en) 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
PT871439E (pt) 1996-01-02 2004-08-31 Aventis Pharma Inc Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)
DE19601938A1 (de) 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
PT882021E (pt) 1996-01-31 2003-07-31 Altana Pharma Ag Novas fenantridinas
JP2000505451A (ja) 1996-02-21 2000-05-09 ダーウィン・ディスカバリー・リミテッド キノロン類およびこれらの治療的使用
AU710825B2 (en) 1996-02-21 1999-09-30 Darwin Discovery Limited Quinolones and their therapeutic use
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
CA2250569C (en) 1996-03-26 2005-05-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel phenanthridines substituted in the 6 position
FR2746800B1 (fr) 1996-03-29 1998-06-05 Jouveinal Inst Rech Diazepino-indoles inhibiteurs de phosphodiesterases 4
FR2754260B1 (fr) 1996-10-04 1998-10-30 Adir Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2187775T3 (es) 1996-05-15 2003-06-16 Altana Pharma Ag Imidazopiridinas.
AU722662B2 (en) 1996-05-20 2000-08-10 Darwin Discovery Limited Quinoline sulfonamides as TNF inhibitors and as PDE-IV inhibitors
IL126557A (en) 1996-05-20 2002-09-12 Darwin Discovery Ltd Quinoline (thio) carboxamides inhibiting TNF or PDE-IV and pharmaceutical preparations containing them
JP4017214B2 (ja) 1996-06-11 2007-12-05 興和創薬株式会社 ５−フェニル−３−ピリダジノン誘導体
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
JPH1072415A (ja) 1996-06-26 1998-03-17 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
ATE211740T1 (de) 1996-06-27 2002-01-15 Pfizer Substituierte indazolderivate
DE19628621A1 (de) 1996-07-16 1998-01-22 Byk Gulden Lomberg Chem Fab Neue 4-substituierte Benzofurane
DE19628622A1 (de) 1996-07-16 1998-01-22 Byk Gulden Lomberg Chem Fab Neue 5-substituierte [2H] Chromene
CA2262502C (en) 1996-07-31 2002-11-26 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same
WO1998005327A1 (en) 1996-08-05 1998-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted aromatic compounds
DK0918746T3 (da) 1996-08-12 2003-08-04 Celgene Corp Immunterapeutiske midler og deres anvendelse til reduktion af cytokinniveauer
DE19632549A1 (de) 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
ATE229516T1 (de) 1996-08-19 2002-12-15 Altana Pharma Ag Benzofuran-4-carboxamide
SI0920426T1 (en) 1996-08-26 2004-04-30 Altana Pharma Ag New thiazole derivatives with phosphodiesterase-inhibiting effect
WO1998008830A1 (de) 1996-08-26 1998-03-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazol-derivate als selektive inhibitoren der pde-iv
AU4298997A (en) 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
CA2264685C (en) 1996-08-27 2002-10-15 Kyoji Noda 2-phenylmorpholin-5-one derivatives and pharmaceutical composition comprising the same
TR199900481T2 (xx) 1996-09-04 1999-06-21 Pfizer Inc. �ndazol t�revleri; fosfodiesteraz tip IV inhibit�rleri olarak kullan�mlar�.
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
US5744473A (en) 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
FR2753969B1 (fr) 1996-09-27 1998-10-30 Adir Nouveaux derives de flavones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU733316B2 (en) 1996-10-04 2001-05-10 Kyorin Pharmaceutical Co. Ltd. Pyrazolopyridylpyridazinone derivatives and process for preparing the same
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
ES2195189T3 (es) 1996-11-11 2003-12-01 Altana Pharma Ag Benzonaftiridinas como agentes terapeuticos bronquiales.
EP0941221B1 (en) 1996-11-20 2003-02-26 ALTANA Pharma AG Substituted dihydrobenzofurans as pde inhibitors
ID19155A (id) 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
SK283270B6 (sk) 1997-01-15 2003-04-01 Altana Pharma Ag Ftalazinóny, farmaceutické prostriedky s ich obsahom a ich použitie
DE59814173D1 (de) * 1997-02-28 2008-04-03 Nycomed Gmbh Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse-agonisten
US6143759A (en) 1997-03-07 2000-11-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrazoles
ID22781A (id) 1997-04-04 1999-12-09 Pfizer Prod Inc Turunan-turunan nikotinamida
WO1998055481A1 (en) 1997-06-03 1998-12-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine
KR19990001101A (ko) 1997-06-12 1999-01-15 손경식 캐테콜 아미노산 유도체, 이의 제조방법 및 그를 함유한 약제 조성물
WO1999005112A1 (en) 1997-07-25 1999-02-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted 6-alkylphenanthridines
CA2297911C (en) 1997-07-25 2007-09-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted 6-phenylphenanthridines
SI0998460T1 (en) 1997-07-25 2004-08-31 Altana Pharma Ag Novel tetrazole derivatives
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
US6254882B1 (en) * 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
KR100629546B1 (ko) * 1997-11-13 2006-09-27 히스타테크, 엘엘씨 소형 펩타이드 및 천식 및 염증을 치료하기 위한 방법
WO1999031071A1 (en) 1997-12-15 1999-06-24 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
EP1042319B1 (en) 1997-12-15 2004-02-04 ALTANA Pharma AG Dihydrobenzofurans
ATE234301T1 (de) * 1998-05-05 2003-03-15 Altana Pharma Ag Neue benzonaphtyridin-n-oxide
IL141335A0 (en) * 1998-08-26 2002-03-10 Smithkline Beecham Corp Therapies for treating pulmonary diseases
US6303145B2 (en) 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions

Also Published As

Publication number Publication date
EP1671651B1 (en) 2009-11-11
CA2381802A1 (en) 2001-03-01
US20060079539A1 (en) 2006-04-13
DE60043318D1 (de) 2010-01-14
JP5038568B2 (ja) 2012-10-03
NO20020815L (no) 2002-02-19
CN1370081A (zh) 2002-09-18
SI1212089T1 (sl) 2006-08-31
US20060205806A1 (en) 2006-09-14
DK1212089T3 (da) 2006-07-24
HU229439B1 (hu) 2013-12-30
NZ517166A (en) 2004-01-30
NO20020815D0 (no) 2002-02-19
AU6701600A (en) 2001-03-19
HUP0203098A3 (en) 2006-07-28
EP1212089A2 (en) 2002-06-12
KR20020020275A (ko) 2002-03-14
US7056936B2 (en) 2006-06-06
JP2003507435A (ja) 2003-02-25
PT1212089E (pt) 2006-08-31
HUP0203098A2 (hu) 2003-01-28
PL356252A1 (en) 2004-06-28
DE60026855T2 (de) 2006-12-07
ATE447952T1 (de) 2009-11-15
ATE320800T1 (de) 2006-04-15
HK1047244B (zh) 2006-10-27
BR0013478A (pt) 2002-04-30
TR200909479T2 (tr) 2012-02-21
HRP20020158A2 (en) 2004-02-29
CZ2002641A3 (cs) 2002-08-14
CN1202865C (zh) 2005-05-25
EP2193808A1 (en) 2010-06-09
TR200201317T2 (tr) 2002-11-21
MXPA02001830A (es) 2002-08-12
WO2001013953A3 (en) 2001-09-20
KR100701904B1 (ko) 2007-04-02
SK287231B6 (sk) 2010-04-07
HRP20020158B1 (en) 2007-08-31
ZA200201389B (en) 2002-08-21
WO2001013953A2 (en) 2001-03-01
SK2552002A3 (en) 2002-06-04
NO328340B1 (no) 2010-02-01
HK1047244A1 (en) 2003-02-14
EP1212089B1 (en) 2006-03-22
ES2260043T3 (es) 2006-11-01
IL147688A (en) 2007-09-20
PL200923B1 (pl) 2009-02-27
BRPI0013478B1 (pt) 2016-12-06
EA200200208A1 (ru) 2002-08-29
EP1671651A1 (en) 2006-06-21
AU777012B2 (en) 2004-09-30
CA2715683A1 (en) 2001-03-01
IL147688A0 (en) 2002-08-14
CZ302882B6 (cs) 2012-01-04
DE60026855D1 (de) 2006-05-11
EA006685B1 (ru) 2006-02-24
CA2381802C (en) 2010-12-07
US20040034087A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
BRPI0013478B8 (pt) medicamento compreendendo inibidor pde e uso de roflumilast
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
EE200200620A (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette nähtud ateroskleroosi ravimiseks ja/või ennetamiseks
IS2575B (is) Ný samverkandi samsetning sem felur í sér róflúmílast og formóteról
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
MA27538A1 (fr) Combinaison synergique comprenant du roflumilast et du (r,r)-formoterol

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25D Requested change of name of applicant approved

Owner name: NYCOMED GMBH (DE)

Free format text: ALTERADO DE: ALTANA PHARMA AG

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: TAKEDA GMBH (DE)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: NYCOMED ASSET MANAGEMENT GMBH (DE)

B25A Requested transfer of rights approved

Owner name: NYCOMED GERMANY HOLDING GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: TAKEDA GMBH (DE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/12/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A PUBLICACAO NA RPI 2396 DE 06/12/2016 QUANTO A FORMATACAO DO DOCUMENTO.

B25A Requested transfer of rights approved
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2474 DE 05-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.